After TauRx Pharmaceutics’ investigational Alzheimer’s treatment hydromethylthionine mesylate (HMTM) was found to slow the disease’s progression it could, if approved, become the first oral treatment targeting the tau protein.

Two biotech firms and a radiochemistry company will develop next-generation targeted alpha-therapies to treat various forms of cancer.

Germany, France, Belgium, Italy and the Netherlands account for the majority of trade in pharmaceutical products across Europe, according to a new report.

Belgium biotechnology company Galapagos has made changes at the top as it prepares to split into two separate entities.

Global pharma company Thermo Fisher Scientific has announced the launch of CorEvitas Adolescent Alopecia Registry, which aims to address an unmet need in the research for adolescent alopecia.

EDX Medical – a clinical diagnostics company founded by Sir Christopher Evans, OBE – has announced the development of a new ‘super test’ for prostate cancer.

To mark last month’s World Cancer Day, a new plan was unveiled by the UK Government to help tackle the impact of cancer across England.

Private medical device and artificial intelligence (AI)-led company, BrightHeart, has revealed two studies which show an improvement to pre-natal care through the use of AI technology which received clearance from the US Food and Drug Administration (FDA) in November 2024.

US-based pharmaceutical company Alvogen has issued a voluntary recall of one batch of its Fentanyl Transdermal System 25mcg/h transdermal patches, amid concerns that patches could be multi-stacked in a single product pouch.

The European Commission (EC) has announced the opening of a new Biotech and Biomanufacturing Hub, supporting start-ups and small-to medium-sized enterprises (SMEs) in bringing new innovations to the EU market.

The University of Sheffield, UK, has announced study results for its trial into the survival rates of patients with operable bladder cancer, finding that those who have immunotherapy before and after the surgery have significantly improved rates of survival.

Moderna, a US-based biopharmaceutical company with an expertise in messenger RNA (mRNA), has announced updates in the two years since it signed a ten-year partnership with the UK Government.